KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Research & Development: 2016-2024

Historic Research & Development for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $190.7 million.

  • Amneal Pharmaceuticals' Research & Development rose 3.69% to $63.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.6 million, marking a year-over-year increase of 12.65%. This contributed to the annual value of $190.7 million for FY2024, which is 16.32% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Research & Development of $190.7 million as of FY2024, which was up 16.32% from $163.9 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Research & Development peaked at $201.8 million during FY2021, and registered a low of $163.9 million during FY2023.
  • In the last 3 years, Amneal Pharmaceuticals' Research & Development had a median value of $190.7 million in 2024 and averaged $183.5 million.
  • Its Research & Development has fluctuated over the past 5 years, first fell by 16.22% in 2023, then grew by 16.32% in 2024.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Research & Development stood at $179.9 million in 2020, then climbed by 12.18% to $201.8 million in 2021, then declined by 3.05% to $195.7 million in 2022, then decreased by 16.22% to $163.9 million in 2023, then rose by 16.32% to $190.7 million in 2024.